[Added entry for NICE approval of Pradaxa. Please see MNTA ‘ReadMeFirst’ for info on M118.]
General #msg-25160571 Anticoagulant market has large potential (WSJ) #msg-26899903 Anticoagulant market has large potential (graphic) #msg-26451612 Venous thromboembolism is a big, big problem #msg-18759853 Overview of the new oral anticoagulants #msg-26701803 Technical overview of traditional anticoagulants
Xarelto (rivaroxaban) #msg-30972846 EMEA approves Xarelto for VTE prevention #msg-31857009 Bayer accelerates Xarelto development #msg-31073048 JNJ submits NDA for VTE prevention #msg-29662519 Rivaroxaban rationale #msg-24337258 Bayer plans 50,000(!)-patient study
Apixaban #msg-31742223 Apixaban fails vs Lovenox in phase-3 #msg-32024540 Tepid phase-2 results in ACS #msg-19134406 PFE, BMY ink $1B collaboration #msg-29928836 Seventh and eighth phase-3 trials begin #msg-21044973 Apixaban non-inferior to Warfarin in phase-2
Pradaxa (dabigatran) #msg-32382343 NICE approves Pradaxa in only six months #msg-27956748 EU approves Pradaxa for VTE prevention #msg-26086079 BI completes enrollment of huge AF trial #msg-25152872 BI starts phase-2 in ACS #msg-21155926 Dabigatran non-inferior to Lovenox in VTE prevention
Lovenox #msg-11669012 Lovenox more cost-effective than heparin? #msg-10569101 Arixtra bests Lovenox in ACS
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.